Bristol Myers (NYSE:BMY) and Pfizer Inc (NYSE:PFE) brings Eliquis in the UK

Bristol Myers Squibb Co. (NYSE:BMY) and Pfizer Inc (NYSE:PFE) revealed their innovative anticoagulant Eliquis in UK.

Eliquis will provide therapy for the prevention of stroke and systemic embolism to patients suffering from non valvular atrial fibrillation (NVAF). Both the companies launched this therapy after winning European regulatory approval in November.

In key clinical study, the medicine has shown greater effectiveness in the treatment of this condition to warfarin, which is the long-established standard of care, except one that showed several unwanted side effects.

The EU approval of the drug is supported by about 24,000 patients who were involved in the Aristotle and Averroes phase III trials.

It was stated by the executive medical director for Bristol-Myers Squibb, Rick Lones that the accessibility of apixaban for doctors and their patients in the UK is a key milestone for the prevention of stroke in patients with NVAF.

In the preceding month, companies provided positive result from Amplify-EXT, an Eliquis study that indicated its benefits in curing recurrent venous thromboembolisms.

Bristol Myers Squibb Co. (NYSE:BMY) hit 14.87% as their profit margin for the last twelve months and had an operating margin of 18.12%. Evaluating management effectiveness, return on equity was maintained at 12.37% in last twelve months. Return on assets for Intel was 8.25%. In the previous 52 weeks the price has traded between $30.64 – $36.34. The last session’s volume of 7.63 million shares competed with the average daily trading volume of 8.78 million shares.

Within the industry, Pfizer Inc. (NYSE:PFE) had a 15.69% profit margin in the last twelve months and an operating margin at 20.12%. Return on equity for this company was 11.05% in the last twelve months. Return on assets was 5.03%. In the last year the stock has moved within a range of $20.75 – $26.09. The last session’s volume of 25.93 million shares competed with the average daily trading volume of 32.17 million shares.

Merck & Co., Inc. (NYSE:MRK) recorded a profit margin of 14.41% for the prior 12 months and an operating margin at 18.79%. Return on equity for this stock was 12.21% while return on assets was -6.48%.

Within the industry, Johnson & Johnson (NYSE:JNJ) had a 12.39% profit margin in the last twelve months and an operating margin at 16.68%. Return on equity for this company was 13.58% in the last twelve months. Return on assets was 7.08%.